Topiramate for Migraine Prevention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Topiramate is an antiepileptic drug that may help prevent migraines. A large study tested topiramate's efficacy and safety in preventing migraines. The study included 483 patients aged 12 to 65 years. These patients had a history of migraines, averaging 3 to 12 monthly. They were randomly assigned to receive topiramate or a placebo. Participants took either 50, 100, or 200 mg of topiramate daily. Both doses were titrated over eight weeks. The primary measure was the change in monthly migraine frequency. Results showed a significant reduction in migraine frequency for those taking topiramate. The 100 mg and 200 mg doses led to reductions of -2.1 and -2.4 migraines. The responder rate was also significantly higher with topiramate. Patients reported fewer migraine days and reduced need for rescue medication. Some adverse events led to treatment discontinuation, including fatigue and nausea. Clinical relevance: This research indicates that topiramate effectively reduces migraine frequency and severity, offering a valuable treatment option for patients.